Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt No Debt
BIOC's Cash-to-Debt is ranked higher than
80% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. BIOC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
BIOC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.86 Max: No Debt
Current: No Debt
Equity-to-Asset 0.09
BIOC's Equity-to-Asset is ranked lower than
88% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIOC: 0.09 )
Ranked among companies with meaningful Equity-to-Asset only.
BIOC' s Equity-to-Asset Range Over the Past 10 Years
Min: -18.63  Med: -0.03 Max: 0.83
Current: 0.09
-18.63
0.83
Piotroski F-Score: 4
Altman Z-Score: -88.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -559.29
BIOC's Operating Margin % is ranked lower than
91% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. BIOC: -559.29 )
Ranked among companies with meaningful Operating Margin % only.
BIOC' s Operating Margin % Range Over the Past 10 Years
Min: -1227100  Med: -9635.78 Max: -559.29
Current: -559.29
-1227100
-559.29
Net Margin % -570.87
BIOC's Net Margin % is ranked lower than
91% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. BIOC: -570.87 )
Ranked among companies with meaningful Net Margin % only.
BIOC' s Net Margin % Range Over the Past 10 Years
Min: -1362900  Med: -11247.71 Max: -570.87
Current: -570.87
-1362900
-570.87
ROA % -266.41
BIOC's ROA % is ranked lower than
95% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. BIOC: -266.41 )
Ranked among companies with meaningful ROA % only.
BIOC' s ROA % Range Over the Past 10 Years
Min: -694.81  Med: -659.5 Max: -197.64
Current: -266.41
-694.81
-197.64
ROC (Joel Greenblatt) % -1374.77
BIOC's ROC (Joel Greenblatt) % is ranked lower than
88% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. BIOC: -1374.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIOC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2717.73  Med: -1614.63 Max: -1249.59
Current: -1374.77
-2717.73
-1249.59
GuruFocus has detected 2 Warning Signs with Biocept Inc $BIOC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8731
Compare:OTCPK:PRFMF, OTCPK:SYGWF, NAS:CDNA, NAS:CHEK, NAS:CAPN, AMEX:PTN, NAS:DRIO, OTCBB:INIS, NAS:TROV, OTCPK:TDSGF, OTCPK:GNWSF, OTCPK:ILIU, NAS:WGBS, NAS:OPGN, OTCPK:LXXGF, OTCPK:CRRVF, OTCPK:MDIT, NAS:GENE, OTCPK:MHTX, NAS:ROKA » details
Traded in other countries:B001.Germany,
Biocept Inc is a cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a standard blood sample or liquid biopsy.

Ratios

vs
industry
vs
history
PB Ratio 55.79
BIOC's PB Ratio is ranked lower than
100% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. BIOC: 55.79 )
Ranked among companies with meaningful PB Ratio only.
BIOC' s PB Ratio Range Over the Past 10 Years
Min: 2.09  Med: 3.93 Max: 55.79
Current: 55.79
2.09
55.79
PS Ratio 7.44
BIOC's PS Ratio is ranked lower than
73% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. BIOC: 7.44 )
Ranked among companies with meaningful PS Ratio only.
BIOC' s PS Ratio Range Over the Past 10 Years
Min: 2.6  Med: 34.18 Max: 195.69
Current: 7.44
2.6
195.69
EV-to-EBIT -2.82
BIOC's EV-to-EBIT is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. BIOC: -2.82 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOC' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.2  Med: -1 Max: -0.1
Current: -2.82
-3.2
-0.1
EV-to-EBITDA -2.86
BIOC's EV-to-EBITDA is ranked lower than
99.99% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. BIOC: -2.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.3  Med: -1 Max: -0.1
Current: -2.86
-3.3
-0.1
Current Ratio 0.35
BIOC's Current Ratio is ranked lower than
96% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. BIOC: 0.35 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.89 Max: 10.2
Current: 0.35
0.02
10.2
Quick Ratio 0.25
BIOC's Quick Ratio is ranked lower than
96% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. BIOC: 0.25 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 2.78 Max: 10.09
Current: 0.25
0.02
10.09
Days Inventory 23.83
BIOC's Days Inventory is ranked higher than
74% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. BIOC: 23.83 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s Days Inventory Range Over the Past 10 Years
Min: 9.26  Med: 16.71 Max: 23.83
Current: 23.83
9.26
23.83
Days Sales Outstanding 14.61
BIOC's Days Sales Outstanding is ranked higher than
97% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. BIOC: 14.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.61  Med: 30.19 Max: 1825
Current: 14.61
14.61
1825
Days Payable 89.67
BIOC's Days Payable is ranked higher than
71% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. BIOC: 89.67 )
Ranked among companies with meaningful Days Payable only.
BIOC' s Days Payable Range Over the Past 10 Years
Min: 50.27  Med: 241.4 Max: 22179.12
Current: 89.67
50.27
22179.12

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 55.79
BIOC's Price-to-Tangible-Book is ranked lower than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.19 vs. BIOC: 55.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIOC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.63  Med: 3.88 Max: 55.79
Current: 55.79
2.63
55.79
Price-to-Median-PS-Value 0.22
BIOC's Price-to-Median-PS-Value is ranked higher than
95% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. BIOC: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1 Max: 3.3
Current: 0.22
0.16
3.3
Earnings Yield (Greenblatt) % -35.46
BIOC's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. BIOC: -35.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -58.1  Med: 0 Max: 0
Current: -35.46
-58.1
0

More Statistics

Revenue (TTM) (Mil) $3.22
EPS (TTM) $ -2.19
Beta2.66
Short Percentage of Float48.03%
52-Week Range $0.74 - 4.29
Shares Outstanding (Mil)22.28

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 7 15
EPS ($) -0.84 -0.71
EPS without NRI ($) -0.84 -0.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:BIOC

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
9:11 am Biocept enters into securities purchase agreements with certain institutional investors... Mar 28 2017
Biocept Announces Pricing of $9.3 Million Financing Mar 28 2017
BIOCEPT INC Files SEC form 10-K, Annual Report Mar 28 2017
BIOCEPT INC Files SEC form 8-K, Shareholder Director Nominations Mar 23 2017
Biocept and OvaScience Post Gains Amid Investor Speculation Mar 23 2017
Biocept Announces Revised Presentation Time at the 27th Annual Oppenheimer Healthcare Conference Mar 20 2017
Biocept to Present at the 27th Annual Oppenheimer Healthcare Conference Mar 15 2017
Couple sue pharma giant for work that led to prison in China Mar 14 2017
Couple sue pharma giant for work that led to prison in China Mar 14 2017
Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell... Mar 14 2017
Trump's choice for FDA has ties to Wall Street, drug makers Mar 11 2017
Trump's choice for FDA has ties to Wall Street, drug makers Mar 11 2017
Trump picks former FDA official to head food and drug agency Mar 10 2017
Trump picks former FDA official to head food and drug agency Mar 10 2017
Biocept to Present at the 29th Annual ROTH Conference Mar 08 2017
BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 07 2017
Biocept Reports Fourth Quarter and Full Year 2016 Financial Results Mar 07 2017
Q4 2016 Biocept Inc Earnings Release - After Market Close Mar 07 2017
Biocept to Release 2016 Fourth Quarter and Full Year Financial Results and Host Investor Conference... Feb 21 2017
Biocept Appoints Michael Terry Senior Vice President Commercial Operations Feb 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)